CENTRALIZED PATHOLOGY UNIT FOR SICKLE CELL DISEASE

镰状细胞病集中病理学单元

• 批准号: 2312533
• 负责人: ELIZABETH A MANCI
• 金额: $ 45.17万
• 依托单位: UNIVERSITY OF SOUTH ALABAMA
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-09-30 至 1995-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2312533
• 关键词: biomedical registry /referral center; blood disorder diagnosis; disease /disorder proneness /risk; electron microscopy; histopathology; human mortality; human tissue; pathology; sickle cell anemia

The purpose of this acquisition is to establish a centralized laboratory to characterize and catalogue autopsy and surgical specimens and correlate pathological findings with clinical data to determine more precisely the causes and risk factors related to mortality in patients with sickle cell disease. All autopsy and surgical specimens from the present Cooperative Study of Sickle Cell Disease (CSSCD) and other studies supported by the Sickle Cell Disease Branch such as: Comprehensive Sickle Cell Center collaborative studies (MRI, Transfusion) etc.; Hydroxyurea Collaborative Study; and the Prophylactic Penicillin Collaborative Study will be analyzed by the Centralized Pathology Unit. The Centralized Pathology Unit will have responsibility to finalize, reproduce, and distribute, to all clinical centers, standardized protocols and forms for the collection of autopsy and surgical samples. Other responsibilities include: 1. To assure compliance of all the clinical centers to the standardized protocols developed by the involved Contractor. 2. Receive and process all surgical and autopsy samples. 3. Perform biochemical and enzyme assays on tissue samples, when appropriate. 4. Provide routine and specialized staining of tissue, as required. 5 Examine tissue specimens using routine or electron microscopy. Tissues requiring special characterization shall be identified by the contractor prior to surgery or autopsy. 6. Conduct characterization, cataloging and interpretation of all samples in relationship to pathology, vascular changes and morphology. 7. Establishment of a registry of slides, of all surgical and autopsy specimens for: CSSCD participants, collaborative, and other studies supported by the Sickle Cell disease Branch. 8. To establish the cause of death, for the previous and new deaths in the CSSCD, collaborative and other studies supported by the sickle Cell Disease Branch. The completion of these objectives will greatly impact on achieving the ultimate goal which is to accurately access the causes and risks factors that contribute to mortality in patients with sickle cell disease.

本次收购的目的是建立一个集中实验室 对尸检和手术标本进行表征和分类并进行关联 病理结果与临床数据相结合，可以更准确地确定 镰状细胞病患者死亡的原因和危险因素 疾病。 目前合作社的所有尸检和手术标本 镰状细胞病研究 (CSSCD) 以及由该组织支持的其他研究 镰状细胞病科如：综合镰状细胞中心 合作研究（MRI、输血）等；羟基脲协作 学习;预防性青霉素合作研究将 由中央病理学单位进行分析。 集中病理学 单位将负责最终确定、复制和分发，以 所有临床中心、标准化方案和收集表格 尸检和手术样本。 其他职责包括： 1. 确保所有临床中心符合标准化 由相关承包商制定的协议。 2. 接收并处理所有手术和尸检样本。 3. 对组织样本进行生化和酶测定，当 合适的。 4. 根据需要提供组织的常规和专门染色。 5 使用常规或电子显微镜检查组织标本。 需要特殊表征的组织应通过以下方式进行识别： 承包商在手术或尸检前。 6. 对所有数据进行表征、编目和解释 与病理、血管变化相关的样本 形态学。 7. 建立所有手术和尸检切片登记册 样本：CSSCD 参与者、协作者和其他 镰状细胞病分会支持的研究。 8. 确定先前死亡和新死亡的死因 CSSCD、镰刀支持的协作研究和其他研究 细胞疾病科。 这些目标的完成将对实现 最终目标是准确获取原因和风险因素 导致镰状细胞病患者死亡。